Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377299 | 0.89 | MAPT (0.53) | GAAMAPTTSHRMEN1KMT2A | |
| SCHEMBL12377304 | 0.85 | MAPT (0.49) | GAAMAPTTSHRMEN1KMT2A | |
| SCHEMBL12377314 | 0.84 | MEN1 (0.40) | MAPK14MEN1KMT2AFFAR1ALDH1A1 | |
| SCHEMBL12377324 | 0.83 | MAPT (0.52) | GAAMAPTTSHRMEN1KMT2A | |
| SCHEMBL12377302 | 0.79 | MAPT (0.49) | GAAMAPTTSHRMEN1KMT2A | |
| SCHEMBL12377282 | 0.78 | MAPT (0.48) | GAAMAPTTSHRMEN1KMT2A | |
| SCHEMBL12412631 | 0.77 | ALOX15 (0.42) | MAPK14GAATSHRMEN1KMT2A | |
| SCHEMBL12413898 | 0.76 | NPC1 (0.53) | GAATSHRKMT2ALMNAAPP | |
| SCHEMBL14641676 | 0.73 | NPC1 (0.49) | GAAMAPTMEN1KMT2APKM | |
| SCHEMBL12377291 | 0.71 | MET (0.43) | GAAMAPTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | MRGPRX1 467/4885MAPK14 1932/4885GAA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.